Market Cap 1.76B
Revenue (ttm) 1.19M
Net Income (ttm) -444.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -37,314.28%
Debt to Equity Ratio 0.00
Volume 6,555,400
Avg Vol 8,187,118
Day's Range N/A - N/A
Shares Out 304.78M
Stochastic %K 13%
Beta 0.57
Analysts Strong Sell
Price Target $23.69

Latest News on IOVA

Iovance Biotherapeutics: Moving To The Next Phase

Oct 3, 2024, 2:43 PM EDT - 3 months ago

Iovance Biotherapeutics: Moving To The Next Phase


Iovance Biotherapeutics to Present at Upcoming Conferences

Sep 3, 2024, 5:00 PM EDT - 4 months ago

Iovance Biotherapeutics to Present at Upcoming Conferences


Iovance (IOVA) stock price could jump by 30% after earnings

May 6, 2024, 9:28 AM EDT - 9 months ago

Iovance (IOVA) stock price could jump by 30% after earnings


Iovance Biotherapeutics Stock Rockets 41% Higher. Here's Why.

Feb 20, 2024, 12:52 PM EST - 11 months ago

Iovance Biotherapeutics Stock Rockets 41% Higher. Here's Why.


Iovance (IOVA) stock price could rocket higher ahead of earnings

Feb 17, 2024, 11:32 PM EST - 11 months ago

Iovance (IOVA) stock price could rocket higher ahead of earnings


FDA Approves First Cellular Treatment For Advanced Melanoma

Feb 16, 2024, 4:16 PM EST - 1 year ago

FDA Approves First Cellular Treatment For Advanced Melanoma


US FDA puts clinical hold on Iovance's cancer therapy trial

Dec 27, 2023, 7:08 AM EST - 1 year ago

US FDA puts clinical hold on Iovance's cancer therapy trial